Nutriband shares surge 18.26% after-hours as it sells 90% of Pocono Pharma to EarthVision Bio for $5M, retaining 10% stake.

Nutriband Inc. surged 18.26% in after-hours trading following the announcement of a $5 million agreement to sell 90% of its subsidiary Pocono Pharmaceutical to EarthVision Bio. The transaction, set to close by Dec. 31, 2025, will leave Nutriband shareholders with a 10% stake in EarthVision Bio and provide proceeds to advance development of AVERSA™ Fentanyl, a potential $80–200 million annual sales opioid patch. The deal aligns with Nutriband’s strategic focus on high-impact product pipelines and leverages EarthVision Bio’s sustainable innovation leadership, led by Intel founder Dr. Gordon Moore and Chevron Europe’s former chairman Dr. Hans Franke. The immediate price reaction reflects investor optimism over the capital infusion and the long-term potential of AVERSA Fentanyl in addressing opioid abuse concerns.